Delayed Gastric Emptying, Diabetes, Glucagon Like Peptide-1 (GLP-1, Morbid Obesity, Risk of Aspiration
Conditions
Keywords
GLP-1, Glucagon like Peptide 1, Aspiration, Gastric empty
Brief summary
The purpose of the study is to determine whether patients taking GLP-1 RAs have increased residual (left behind), gastric (stomach), contents due to delayed gastric emptying when following standard preoperative fasting guidelines.
Interventions
DRUGGlucagon-Like Peptide-1 receptor agonists
GLP-1 RAs: Glucagon like peptide-1 receptor agonists, this includes patients who are on Liraglutide, Semaglutide, Dulaglutide and Tirzepatide.Tirzepatide which is a combined GLP-1 RA/glucose-dependent insulinotropic polypeptide (GIP) agonist is included as a part of GLP-1 RAs.
DIAGNOSTIC_TESTPoint of Care Gastric Ultrasound
A gastric ultrasound following a standard NPO period to determine gastric contents and risk of aspiration during surgery.
Sponsors
Children's Hospital Medical Center, Cincinnati
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
10 Years to 25 Years
Healthy volunteers
Yes
Inclusion criteria
* Body Mass Index over 35 * Type 2 Diabetes * Currently taking GLP01 RA agonist (for GLP 1 group) * Not taking GLP-1 RA agonist (for control group)
Exclusion criteria
* Diagnosis of gastroparesis * patient refusal to participate * Previous gastric bypass or any other gastric surgery * Currently on peritoneal dialysis * Abdominal pathology * Gastro-intestinal obstruction * Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Aspiration Risk determined by POGUS | Two years | Difference between control group and GLP-1 group. Measured by Gastric contents during Point of Care Gastric Ultrasound. |
Countries
United States
Outcome results
None listed